Zydus Cadila Strides Ahead With NASH Filing In India
API Manufacturing Unit In Dabhasa Receives NAI
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
